术后化疗疗程对早期上皮性卵巢癌预后的影响

目的：比较不同化疗疗程对早期卵巢上皮癌患者生存率和无瘤生存率的影响。方法180例患者按预后风险因素及化疗疗程分组，无瘤生存率及生存率采用Kaplan-Meier法估算，采用Log-Rank检验进行比较。结果≤4疗程（Ⅰ组）及﹥4疗程（Ⅱ组）5年总生存率（5-OS）、2年无瘤生存率（2-DFS）及5年无瘤生存率（5-DFS）分别为54.1%、51.6%、47.8%，48.3%、41.8%、40.0%；两组5-OS、2-DFS 及5-DFS 的差异均无统计学意义（P=0.926，P=0.713）。高危组和低危组患者5-OS、2-DFS 及5-DFS 分别为45.6%、84.7%，38.5%、93.5%，32.9%、77.5%；两组5-OS、2-DFS及5-DFS差异有统计学意义（P均=0.000）。高危组中≤4疗程（A1组）及﹥4疗程（A2组）5-OS、2-DFS及5-DFS分别为39.6%、48.5%，26.8%、43.7%，26.8%、36.0%；两组5-OS差异无统计学意义（P=0.314），A1组2-DFS及5-DFS均低于A2组（P=0.011）。低危组中≤4疗程化疗及﹥4疗程5-OS、2-DFS及5-DFS分别为85.1%、83.3%，95.0%、90.9%，77.7%、77.9%；两组5-OS、2-DFS及5-DFS差异无统计学意义（P＞0.5）。结论高危组早期上皮性卵巢癌患者术后予大于4疗程化疗可提高其无瘤生存率。

The benefit of different adjuvant chemotherapy cycles in early-stage epithelial ovarian cancer

Objective To compare 5-year overall survival rate （5-OS） and disease-free survival rate （DFS） on early stage epithelia ovarian cancer patients with different chemotherapy cycles. Methods One hundred and eighty patients were divided into different groups based on the cycles of chemotherapy and prognostic risk factors. SPSS13.0 Kaplan-Meier survival analyses were performed to estimate 5-OS and DFS. Log-rank test was employed to compare the differences in 5-OS and DFS. Results The 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy was 54.1%, 51.6%, 47.8%and 48.3%, 41.8%, 40.0%. The 5-OS, the 2-DFS and 5-DFS with different cy-cles of chemotherapy was not significantly different between the two groups （P=0.926, P=0.713）. The 5-OS, 2-DFS and 5-DFS of the high-risk group and the low-risk group were 45.6%, 84.7%, 38.5% and 93.5%, 32.9%, 77.5%. The 5-OS, the 2-DFS and 5-DFS with different cycles of chemotherapy were significantly different between the two groups （P=0.000, P= 0.000）. In the high-risk group, the 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy was 39.6%, 48.5%, 26.8% and 43.7%, 26.8%, 36.0%. The 5-OS was not significantly different be-tween the two groups （P= 0.314）. The 2-DFS and 5-DFS of more than 4 chemotherapy was higher （P= 0.011）. In the low-risk group, the 5-OS, 2-DFS and 5-DFS of less than 4 cycles of chemotherapy and more than 4 chemotherapy were 85.1%, 83.3%, 95.0% and 90.9%, 77.7%, 77.9%. The 5-OS, the 2-DFS and 5-DFS were not significantly different between the two groups （P= 0.596, P= 0.760）. Conclusion More than 4 cycles of chemotherapy can improve the dis-ease-free survival rate in high-risk early stage epithelial ovarian cancer.